CHMA - Chiasma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
6.20
-0.10 (-1.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.30
Open6.31
Bid0.00 x 800
Ask0.00 x 900
Day's Range6.08 - 6.36
52 Week Range1.20 - 8.29
Volume319,710
Avg. Volume285,444
Market Cap196.961M
Beta (3Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-1.35
Earnings DateAug 7, 2019 - Aug 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price
    Simply Wall St.8 days ago

    One Thing To Remember About The Chiasma, Inc. (NASDAQ:CHMA) Share Price

    Anyone researching Chiasma, Inc. (NASDAQ:CHMA) might want to consider the historical volatility of the share price...

  • Benzinga25 days ago

    18 Stocks Joining The Russell Indices

    The Russell 2000 Index is a small-cap stock market index that includes the bottom 2,000 companies found in the Russell 3000 index. The Russell Microcap Index includes the 1,000 smallest securities found ...

  • Benzinga25 days ago

    The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on June 27) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) (received ...

  • GlobeNewswire26 days ago

    Chiasma Set to Join Russell 3000® Index

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that the company has been selected for inclusion in the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • GlobeNewswire26 days ago

    Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials

    In the Phase 3 CHIASMA OPTIMAL trial, which is being conducted under a special protocol assessment agreement, or SPA, with FDA, the company announced that the last enrolled patient completed the trial earlier this month. The company now expects to release top-line data by mid-Q3.  Importantly, all 56 patients enrolled in the trial reached the final 36-week visit with no patient dropouts from the trial reported through the 36-week double-blind and controlled phase of the trial.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 5) Array Biopharma Inc (NASDAQ: ARRY ) Arrowhead Pharmaceuticals ...

  • GlobeNewswire2 months ago

    Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced a management transition intended to further strengthen the Company’s leadership team ahead of the anticipated commercial availability of Mycapssa®. As part of the transition, the Company has appointed pharmaceutical commercial veteran Raj Kannan as Chief Executive Officer.  The Company’s current Chief Executive Officer, Mark Fitzpatrick, will continue to serve as President.

  • Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%
    Zacks2 months ago

    Chiasma (CHMA) Catches Eye: Stock Jumps 9.7%

    Chiasma (CHMA) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

  • Will Chiasma to Surge Higher?
    Zacks2 months ago

    Will Chiasma to Surge Higher?

    As of late, it has definitely been a great time to be an investor Chiasma.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CHMA earnings conference call or presentation 9-May-19 9:00pm GMT

    Q1 2019 Chiasma Inc Earnings Call

  • GlobeNewswire2 months ago

    Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement

    Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance.

  • Associated Press2 months ago

    Chiasma: 1Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. Chiasma shares have risen 99% since the beginning of the year. In the final minutes of trading on Thursday, shares hit ...

  • GlobeNewswire2 months ago

    Chiasma Reports First Quarter 2019 Results

    During the first quarter of 2019, Chiasma continued to advance its international Phase 3 clinical trial, referred to as CHIASMA OPTIMAL (Octreotide capsules vs. Placebo Treatment In MultinationAL centers), which, if positive, could support potential regulatory approval in the United States of its investigational octreotide capsules, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly. Chiasma anticipates the release of top-line data from this trial during the third quarter of 2019, with an NDA resubmission planned by year-end 2019.

  • GlobeNewswire3 months ago

    Chiasma to Report First Quarter Financial Results on May 9, 2019

    WALTHAM, Mass., April 30, 2019 -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • Shareholders Are Raving About How The Chiasma (NASDAQ:CHMA) Share Price Increased 312%
    Simply Wall St.3 months ago

    Shareholders Are Raving About How The Chiasma (NASDAQ:CHMA) Share Price Increased 312%

    For many, the main point of investing in the stock market is to achieve spectacular returns. When an investor finds a multi-bagger (a stock that goes up over 200%), it makes a big difference to their portfolio. For examp...

  • GlobeNewswire4 months ago

    Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has closed its previously announced underwritten public offering of 7,263,158 shares of its common stock at a price to the public of $4.75 per share for gross proceeds of approximately $34.5 million. Chiasma anticipates using the proceeds from the offering primarily for development costs, including the conduct of its ongoing Phase 3 clinical trials of octreotide capsules, preparation for potential commercialization in the United States, and for working capital and other general corporate purposes. H.C. Wainwright & Co., Roth Capital Partners, Brookline Capital Markets, a division of CIM Securities, LLC and LifeSci Capital LLC acted as co-managers for the offering.

  • GlobeNewswire4 months ago

    Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced the pricing of an underwritten public offering of 6,315,790 shares of its common stock at a price to the public of $4.75 per share, before deducting underwriting discounts and commissions and other offering expenses payable by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to an additional 947,368 shares of its common stock at the public offering price, less underwriting discounts and commissions.

  • Benzinga4 months ago

    5 Stocks Moving In Thursday's After-Hours Session

    Gainers: Science Applications International Corp (NYSE: SAIC ) shares are up 7 percent after reporting a fourth-quarter earnings beat. Adjusted earnings came in at $1.17, beating estimates by 38 cents. ...

  • GlobeNewswire4 months ago

    Chiasma Announces Proposed Offering of Common Stock

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has commenced an underwritten public offering of its common stock. In addition, Chiasma expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire4 months ago

    Chiasma Announces Three Poster Presentations at ENDO 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced three poster presentations at ENDO 2019: The Endocrine Society’s Annual Meeting and Expo, which is being held March 23-26 in New Orleans. William Ludlam, MD, PhD, Senior Vice President of Clinical Development and Medical Affairs, said, “We are pleased to present three posters at ENDO this year to further educate the endocrinology community on the ongoing challenges associated with the maintenance treatment of adults suffering from acromegaly. Mark Fitzpatrick, Chief Executive Officer of Chiasma, commented, “Our octreotide capsules product candidate, which we have conditionally trade named MYCAPSSA®, is currently being evaluated in two Phase 3 clinical trials and, if approved, could represent a new treatment paradigm by being the first orally-administered somatostatin analog.

  • GlobeNewswire5 months ago

    Chiasma Reports Fourth Quarter and Year End 2018 Results

    On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA®, expected in Q3 2019 Assuming positive OPTIMAL data,.

  • GlobeNewswire5 months ago

    Chiasma to Participate in Three Investor Conferences in March

    WALTHAM, Mass., March 04, 2019 -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious.

  • GlobeNewswire5 months ago

    Chiasma Announces Support for Rare Disease Day 2019

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of Rare Disease Day 2019. “The theme of Rare Disease Day 2019, ‘Bridging health and social care,’ strikes at the heart of what we are working towards here at Chiasma to improve the lives of people afflicted with acromegaly,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.

  • Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?
    Simply Wall St.5 months ago

    Have Insiders Been Buying Chiasma, Inc. (NASDAQ:CHMA) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share pricesRead More...

  • GlobeNewswire7 months ago

    Chiasma Previews Important Upcoming Milestones

    Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today previewed anticipated upcoming corporate milestones and commented on the significant progress made by the company in 2018. “During 2018, we completed the required enrollment in both of our Phase 3 clinical trials of our investigational octreotide capsules product candidate, which we have conditionally trade-named Mycapssa®, and with those trials progressing as planned, we believe we have set the stage for a catalyst-rich 2019 including the announcement of topline data evaluating Mycapssa’s efficacy as potentially the first oral somatostatin analog for the maintenance therapy of adult acromegaly patients,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.